3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
7
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid
2
Gastrointestinal Stromal Tumors
2
Bone Marrow Diseases
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Blast Crisis
1
Interventions
pegaspargase
1
nilotinib
1
merphos
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
Vorinostat
1
Vincristine
1
Mitoxantrone
1
Methotrexate
1
Dexamethasone
1
Decitabine
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
×
nilotinib
×
Clear all
NCT00905398
2015-07-09
ALLPhi
Universidade Federal do Rio de Janeiro
Phase 1/2
Terminated
8 enrolled